[Estramustinphosphate in the treatment of prostatic cancer].
OBJECTIVE
This study describes our experience in the treatment of disseminated prostatic cancer with stramustine phosphate.


METHODS
We reviewed our series of 41 patients with disseminated prostatic cancer; of these, 6 were treated with stramustine phosphate. Patient age, clinical features, tumor stage and diagnostic methods utilized were analyzed. All patients received 600 mg/day oral stramustine in two doses.


RESULTS
All 6 patients treated with stramustine phosphate showed clinical improvement, the levels of tumor markers returned to normal and bone metastasis disappeared. Moreover, no side effects were observed.


CONCLUSIONS
Further research is necessary on the effective use of stramustine phosphate and at the appropriate time in order to obtain the best results as there is no other alternative except radical surgery and at an early stage.
Sánchez Gómez
E
E
Servicio de Urología, Hospital Universitario Virgen del Rocio, Sevilla, España.
Pérez Pérez
M
M
Huesa Martínez
J I
JI
Campoy Moreno
J R
JR
D000368:Aged; D003131:Combined Modality Therapy; D004961:Estramustine / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery; D012074:Remission Induction; D013997:Time Factors
D004961:Estramustine